Abdul El-Sayed, a Democratic candidate for the U.S. Senate in Michigan, stated that government restrictions on medical treatments for transgender minors infringe on the physician-patient relationship. Speaking at a rally at Michigan State University, El-Sayed emphasized that healthcare decisions should be made solely between a patient—or their parents if the patient is under 18—and their doctor. The remarks come as the Trump administration has moved to limit access to certain gender-affirming procedures for children, including hormone therapy and surgeries, which the administration has characterized as experimental.
El-Sayed, who previously served as the head of the Detroit Health Department, has highlighted his background as a physician in his campaign, noting that if elected, he would be the first doctor to serve as a Democratic senator in 50 years. However, Fox News Digital reported that El-Sayed has never held a medical license in either Michigan or New York. Despite this, El-Sayed argued that the credibility of medical professionals should not be undermined by political intervention, asserting that experts are the appropriate authority for determining necessary care.
What the Right Is Saying
Conservative critics and the Trump administration argue that the government has a duty to oversee medical practices that lack robust scientific consensus, particularly when involving minors. The Trump administration has taken steps to restrict what it terms "sex-rejecting" procedures for children, including hormone therapy and surgeries. This stance is reflected in recent agreements between the Justice Department and major medical institutions, such as Mount Sinai, Texas Children's Hospital, the Cleveland Clinic Foundation, and Connecticut Children's Hospital, to halt these procedures for children.
Critics also focus on El-Sayed's professional credentials. Fox News Digital previously reported that El-Sayed has never held a medical license in Michigan or New York, despite his campaign branding him as a physician. This discrepancy has fueled arguments that his defense of medical autonomy relies on a professional status that has not been fully realized in the states where he is running for office.
Furthermore, the Right to Try Act cited by El-Sayed was designed for terminally ill adults with no other options, a context critics argue is distinct from elective gender-affirming care for minors. Conservative commentators suggest that equating these two scenarios ignores the differences in medical necessity and the protective role of the state regarding children's long-term health outcomes.
What the Left Is Saying
Democratic supporters and El-Sayed himself frame the issue as a matter of bodily autonomy and the sanctity of the clinical relationship. El-Sayed stated, "I don't think the government gets to have a say about what healthcare is provided in what circumstances and why." He argued that the standard for healthcare decisions must remain in the hands of those directly involved: the patient and the provider.
To support his position, El-Sayed pointed to the Right to Try Act, a bipartisan law that allows terminally ill patients to access experimental drugs not yet approved by the FDA. "Conservatives fought for a very long time for this legislation called 'Right to Try' legislation, which is the idea that the government couldn't tell you [that] you couldn't have a certain medication," El-Sayed said. He contended that this precedent establishes that Republicans agree healthcare decisions should remain between individuals and their providers, a standard he argues should apply to transgender youth care as well.
El-Sayed further noted that he believes there is significant disinformation surrounding reproductive rights and healthcare for transgender individuals. "The place where the rubber meets the rope is in that clinical room between a patient and a provider, and that to me is the center we should engage on," he stated. His campaign platform, which includes a promise of Medicare-for-all, posits that even if the government funds healthcare, it should not dictate specific treatment protocols within the doctor-patient dynamic.
What the Numbers Show
The legal and medical landscape regarding transgender youth care is currently under significant scrutiny. The World Professional Association for Transgender Health (WPATH), whose guidelines are adopted by major organizations like the American Academy of Pediatrics, is facing a lawsuit from the Federal Trade Commission (FTC). The FTC alleges that WPATH misled parents regarding the "medical consensus and medical necessity, as well as the safety and effectiveness" of sex-change procedures.
The FTC's complaint specifically cites a failure to disclose potential side effects of "cross-sex" hormones, listing issues such as incontinence, erectile pain, mood disturbances, pelvic pain, and vaginal pain. The research on the efficacy of treating gender dysphoria in individuals using puberty blockers and cross-sex hormones is described in the source material as limited.
Internationally, countries with socialized medicine have implemented stricter regulations for minors seeking these treatments. In England, the National Health Service (NHS) has placed restrictions on gender-affirming care for children, reflecting a broader global trend of reviewing the safety and long-term impacts of such interventions for younger populations.
The Bottom Line
El-Sayed's comments underscore a central tension in the 2026 political landscape: the conflict between individual medical autonomy and government regulatory oversight, particularly concerning minors. While El-Sayed argues that the physician-patient relationship should be insulated from political interference, the Trump administration and its allies contend that the state has an obligation to restrict treatments they deem experimental or insufficiently proven for children.
The outcome of the FTC's lawsuit against WPATH and the implementation of federal restrictions on pediatric care will likely shape the legal boundaries of this debate. For El-Sayed, the challenge will be balancing his campaign's focus on healthcare access and autonomy against ongoing questions regarding his medical credentials and the evolving scientific consensus on gender-affirming care for youth.